Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9

Hera Saqub(California Pacific Medical Center), Altaf A. Dar(Vanderbilt University Medical Center)
Scientific Reports
October 28, 2020
Cited by 89


Related Papers